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Sir,
We read with interest the paper by Reitsamer et al (2004)
regarding SLN biopsy without axillary node dissection in a group
of 200 patients proven sentinel node negative based on histology
(frozen and paraffin-embedded sections) and immunhistochem-
istry. After a mean follow-up of 36 months (22–56 months), no
axillary recurrence has been found so far.
In our own collective, we surveyed 120 consecutive patients with
the sentinel technique. We started at the end of 2001, after
completion of a learning phase with 54 patients. We used the same
combination of radionuclide and blue dye labelling as described in
the paper by Reitsamer et al (2004). In these patients, the sentinel
node was detectable in 93.3% (n¼112). A total of 25 patients
(22.3%) had a positive sentinel node (proven by histology or
immunhistochemistry), which led to primary or secondary
complete axillary dissection. After a mean follow-up of 13.5
months (2–27 months), we have found up until this day one case
of axillary recurrence. In contrast to the paper of Reitsamer et al
(2004), the rate of positive sentinel nodes in our experience was
much lower (22.3 vs 39.0%). A possible reason for this could be
due to the fact that we discriminate the patients for the sentinel
node technique not only by clinically negative axillae but also by
sonographic negative axillae. Patients with sonographic conspic-
uous nodes are excluded from the sentinel node biopsy.
In our opinion, the sentinel node technique is well established
in clinical settings. The data of different large studies show
a sensitivity of about 92% for the sentinel node technique
(Kuehn et al, 2004). This means that approximately eight out
of 100 patients could be mis-staged, which might lead to an
inadequate adjuvant treatment and increased regional re-
currence. On the other hand, a much larger number of patients
will be spared the morbidity of axillary dissection, with risk
of lymphoedema, seroma and paraesthesia of the ipsilateral
arm. Ideally, we should wait for the results of large controlled
trials, such as NSABP-32, to calculate the estimated survival
of patients, but these trials are not due to be completed until
2006 (Veronesi et al, 2003; Beechey-Newman 2004). From other
studies, we know that local recurrence does not seem to in-
fluence the survival of the patients (Fisher et al, 2002); the
therapeutic use of complete axillary dissection is still contro-
versial (Recht and Houlihan, 1995) and today most of our patients
receive adjuvant therapy after primary surgery. So, with regard
to the large number of data, we can no longer accept
the assessment by Reitsamer et al (2004) that ‘axillary lymph
node dissection should not be abandoned as standard care for
SLN-negative patients’. If nothing else, our informed patients
expect us to know, to be trained in and to apply this technique in
our routine treatment.
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